The ascendancy of Viagra and its impact on the drug landscape presents a intricate question for investors. While the first sales data were remarkable, the patent has lapsed, leading to a flood of generic alternatives that are chipping away at profit. Furthermore, the market is facing challenges related to aging trends and evolving healthcare reg… Read More